Market revenue in 2023 | USD 172.4 million |
Market revenue in 2030 | USD 334.9 million |
Growth rate | 9.9% (CAGR from 2023 to 2030) |
Largest segment | Epinephrine |
Fastest growing segment | Immunotherapies |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Antihistamines, Epinephrine, Immunotherapies, Other Drug Class |
Key market players worldwide | Nestle SA, Sanofi SA, DBV Technologies SA ADR, PureTech Health PLC, Regeneron Pharmaceuticals Inc, Teva Pharmaceutical Industries Ltd ADR, Protagonist Therapeutics Inc, Aravax, Alladapt Immunotherapeutics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to peanut allergy treatment market will help companies and investors design strategic landscapes.
Epinephrine was the largest segment with a revenue share of 46.17% in 2023. Horizon Databook has segmented the U.S. peanut allergy treatment market based on antihistamines, epinephrine, immunotherapies, other drug class covering the revenue growth of each sub-segment from 2018 to 2030.
This surge in cases is a growing concern for public health, driving the demand for effective treatment solutions. Among the affected, about 1 million children in the U.S. have peanut allergy, and only one in five of these children will outgrow their allergy as they grow older, emphasizing the need for sustained treatments from childhood to adulthood.
Furthermore, a notable trend emerges regarding diagnosis, with nearly 58.9% of adults developing peanut allergy in adulthood lacking a formal diagnosis from a physician. This points to potential underdiagnosis and unmet medical needs among adult-onset cases, highlighting the need for improved diagnostic practices.
However, approximately one in five adults with peanut allergy, regardless of onset age, visited the emergency department due to food allergy-related issues in the past year. This consistent demand for emergency care highlights the necessity for accessible treatments and prevention measures in the peanut allergy market.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. peanut allergy treatment market , including forecasts for subscribers. This country databook contains high-level insights into U.S. peanut allergy treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account